粪便排放的挥发性有机化合物作为结直肠癌生物标志物
研究评估粪便挥发性有机化合物作为结直肠肿瘤生物标志物的效用,收集137例症状患者和英国肠道癌症筛查计划参与者的粪便,在结肠镜检查前进行顶空提取和气相色谱-质谱联用分析。发现2-丙醇在癌症样本中显著更丰富(P < 0.0001,q = 0.004),AUROC为0.76;与3-甲基丁酸联合后AUROC为0.82,灵敏度87.9%(95% CI 0.87-0.99),特异度84.6%(95% CI 0.65-1.0)。
要点
- 粪便挥发性有机化合物分析可能对结直肠腺癌具有优于其他粪便生物标志物的诊断能力。
- 2-丙醇在癌症样本中显著更丰富(P < 0.0001,q = 0.004),AUROC为0.76。
- 三种挥发性有机化合物组合(2-丙醇、己-2-酮和3-甲基丁酸乙酯)存在时患癌可能性为六倍(P < 0.0001)。
核心结论
- 挥发性有机化合物分析在识别结直肠腺癌方面可能具有优于其他粪便生物标志物(包括英国目前使用的那些)的诊断能力。
研究设计与样本
- 研究收集症状患者和英国肠道癌症筛查计划参与者的粪便,在结肠镜检查前进行顶空提取和气相色谱-质谱联用分析,使用逻辑回归建模和10折交叉验证测试潜在生物标志物。
- 共纳入137名参与者(平均年龄64岁[范围22-85],54%为男性):60例无肿瘤,56例有腺瘤性息肉,21例有腺癌。
主要发现
- 2-丙醇在癌症样本中显著更丰富(P < 0.0001,q = 0.004),ROC曲线下面积(AUROC)为0.76。
- 2-丙醇与3-甲基丁酸联合时AUROC为0.82,灵敏度87.9%(95% CI 0.87-0.99),特异度84.6%(95% CI 0.65-1.0)。
- 使用特定挥发性有机化合物存在/缺失的逻辑回归分析识别出三种挥发性有机化合物组合(2-丙醇、己-2-酮和3-甲基丁酸乙酯)的AUROC为0.73,如果所有三种挥发性有机化合物都存在,患癌可能性为六倍(P < 0.0001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Colorectal cancer remains a leading cause of mortality and morbidity. The UK Bowel Cancer Screening Programme (BCSP) has demonstrated that detection of colorectal cancer at an earlier stage and identification of advanced pre-malignant adenomas reduces mortality and morbidity. AIM: To assess the utility of volatile organic compounds as a biomarker for colorectal neoplasia. METHODS: Faeces were collected from symptomatic patients and people participating in the UK BCSP, prior to colonoscopy. Headspace extraction followed by gas chromatography mass spectrometry was performed on faeces to identify volatile organic compounds. Logistic regression modelling and 10-fold cross-validation were used to test potential biomarkers. RESULTS: One hundred and thirty-seven participants were included (mean age 64 years [range 22-85], 54% were male): 60 had no neoplasia, 56 had adenomatous polyp(s) and 21 had adenocarcinoma. Propan-2-ol was significantly more abundant in the cancer samples (P < 0.0001, q = 0.004) with an area under ROC (AUROC) curve of 0.76. When combined with 3-methylbutanoic acid the AUROC curve was 0.82, sensitivity 87.9% (95% CI 0.87-0.99) and specificity 84.6% (95% CI 0.65-1.0). Logistic regression analysis using the presence/absence of specific volatile organic compounds, identified a three volatile organic compound panel (propan-2-ol, hexan-2-one and ethyl 3-methyl- butanoate) to have an AUROC of 0.73, with a person six times more likely to have cancer if all three volatile organic compounds were present (P < 0.0001). CONCLUSIONS: Volatile organic compound analysis may have a superior diagnostic ability for the identification of colorectal adenocarcinoma, when compared to other faecal biomarkers, including those currently employed in UK. Clinical trial details: National Research Ethics Service Committee South West - Central Bristol (REC reference 14/SW/1162) with R&D approval from University of Liverpool and Broadgreen University Hospital Trust (UoL 001098).
引用
- Bond A, Greenwood R, Lewis S, et al. Volatile organic compounds emitted from faeces as a biomarker for colorectal cancer. Aliment Pharmacol Ther. 2019. PMID: 30828825. doi:10.1111/apt.15140
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。